trial · primary record
Decitabine
Acute Myeloid Leukemia
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 129 |
| Primary completion | 2028-01-01 |
| Primary endpoint | Maximum tolerated dose of the combination drugs (Phase I) |
| Registry ID | NCT03661307 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:55:07.020Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03661307
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.